Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.41) by 39.02 percent. This is a 35.9 percent increase over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $2.46 million which beat the analyst consensus estimate of $740.00 thousand by 232.57 percent. This is a 13.50 percent decrease over sales of $2.85 million the same period last year.